IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium
IDEAYA Biosciences (Nasdaq:IDYA) announced a late-breaking oral presentation of Phase 1 expansion results for IDE397, a first-in-class, oral MAT2A inhibitor, in MTAP-deletion urothelial and non-small cell lung cancer (NSCLC) patients. The presentation will take place at the 36th EORTC-NCI-AACR Symposium in Barcelona, Spain, on October 25, 2024.
Dr. Benjamin Herzberg from Columbia University will present the results in a plenary session. Additionally, IDEAYA will present two posters: one on the combinatorial inhibition of MAT2A and PRMT5 in MTAP-deleted tumors, and another on IDE161, a potential first-in-class PARG inhibitor targeting solid tumors with replication stress and DNA repair vulnerabilities.
IDEAYA Biosciences (Nasdaq:IDYA) ha annunciato una presentazione orale straordinaria dei risultati dell'espansione della Fase 1 per IDE397, un inibitore MAT2A orale di prima classe, in pazienti con cancro uroteliale e carcinoma polmonare non a piccole cellule (NSCLC) con delezione di MTAP. La presentazione si terrà al 36° Simposio EORTC-NCI-AACR a Barcellona, Spagna, il 25 ottobre 2024.
Il Dr. Benjamin Herzberg della Columbia University presenterà i risultati in una sessione plenaria. Inoltre, IDEAYA presenterà due poster: uno sull'inibizione combinatoria di MAT2A e PRMT5 nei tumori con delezione di MTAP, e l'altro su IDE161, un potenziale inibitore di PARG di prima classe che prende di mira i tumori solidi con stress da replicazione e vulnerabilità nella riparazione del DNA.
IDEAYA Biosciences (Nasdaq:IDYA) anunció una presentación oral de última hora sobre los resultados de la expansión de la Fase 1 para IDE397, un inhibidor MAT2A oral de primera clase, en pacientes con cáncer urotelial y cáncer de pulmón no microcítico (NSCLC) con deleción de MTAP. La presentación se llevará a cabo en el 36º Simposio EORTC-NCI-AACR en Barcelona, España, el 25 de octubre de 2024.
El Dr. Benjamin Herzberg de la Universidad de Columbia presentará los resultados en una sesión plenaria. Además, IDEAYA presentará dos pósteres: uno sobre la inhibición combinatoria de MAT2A y PRMT5 en tumores con deleción de MTAP, y otro sobre IDE161, un potencial inhibidor de PARG de primera clase que apunta a tumores sólidos con estrés de replicación y vulnerabilidades en la reparación del ADN.
IDEAYA 바이오사이언스(Nasdaq:IDYA)는 MTAP 결실을 가진 요로상피암 및 비소세포 폐암(NSCLC) 환자를 위한 IDE397, 첫 번째 클래스의 경구 MAT2A 억제제의 1상 확장 결과에 대한 긴급 구두 발표를 발표했습니다. 발표는 2024년 10월 25일 스페인 바르셀로나에서 열리는 제36회 EORTC-NCI-AACR 심포지엄에서 진행됩니다.
컬럼비아 대학교의 베냐민 헤르스버그 박사가 전체 세션에서 결과를 발표합니다. 또한 IDEAYA는 두 개의 포스터를 발표합니다: 하나는 MTAP 결실 종양에서 MAT2A와 PRMT5의 조합 억제에 관한 것이고, 또 하나는 복제 스트레스와 DNA 수리 취약성을 가진 고형 종양을 표적하는 IDE161, 잠재적인 최초의 PARG 억제제에 관한 것입니다.
IDEAYA Biosciences (Nasdaq:IDYA) a annoncé une présentation orale urgente des résultats de l'expansion de la Phase 1 pour IDE397, un inhibiteur MAT2A oral de première classe, chez des patients atteints de cancer urotélial et de cancer du poumon non à petites cellules (NSCLC) avec délétion de MTAP. La présentation aura lieu au 36ème Symposium EORTC-NCI-AACR à Barcelone, Espagne, le 25 octobre 2024.
Le Dr Benjamin Herzberg de l'Université de Columbia présentera les résultats lors d'une session plénière. De plus, IDEAYA présentera deux affiches : l'une sur l'inhibition combinatoire de MAT2A et PRMT5 dans les tumeurs avec délétion de MTAP, et l'autre sur IDE161, un potentiel inhibiteur de PARG de première classe ciblant les tumeurs solides présentant un stress de réplication et des vulnérabilités dans la réparation de l'ADN.
IDEAYA Biosciences (Nasdaq:IDYA) gab eine kurzfristige mündliche Präsentation der Ergebnisse der Phase-1-Erweiterung für IDE397 bekannt, einen ersten seiner Art, oralen MAT2A-Inhibitor, bei Patienten mit MTAP-deletierten urotelialen und nicht-kleinzelligem Lungenkrebs (NSCLC). Die Präsentation findet am 36. EORTC-NCI-AACR-Symposium in Barcelona, Spanien, am 25. Oktober 2024 statt.
Dr. Benjamin Herzberg von der Columbia University wird die Ergebnisse in einer Plenarsitzung vorstellen. Zusätzlich wird IDEAYA zwei Poster präsentieren: eines zur kombinatorischen Hemmung von MAT2A und PRMT5 in MTAP-deletierten Tumoren und ein weiteres zu IDE161, einem potenziellen ersten PARG-Inhibitor, der solide Tumoren mit Replikationsstress und DNA-Reparaturanfälligkeiten anvisiert.
- Presentation of Phase 1 expansion results for IDE397, a first-in-class MAT2A inhibitor
- IDE397 targets MTAP-deletion urothelial and non-small cell lung cancer
- Late-breaking oral presentation at a major oncology symposium
- Additional poster presentations on MAT2A and PARG programs
- None.
Insights
The late-breaking oral presentation of IDE397's Phase 1 expansion results in MTAP-deletion lung and urothelial cancer is a significant development for IDEAYA Biosciences. IDE397, as a first-in-class MAT2A inhibitor, represents a novel approach in precision oncology. The focus on MTAP-deleted tumors indicates a targeted strategy that could potentially address an unmet medical need.
Key points to consider:
- The presentation at a major oncology symposium (EORTC-NCI-AACR) suggests the data is considered important by the scientific community.
- Phase 1 expansion results often provide initial efficacy and safety signals, which are important for determining the potential of a new drug.
- The inclusion of both NSCLC and urothelial cancer patients broadens the potential application of IDE397.
- Additional poster presentations on preclinical data for MAT2A and PARG programs indicate a robust pipeline and ongoing research efforts.
For investors, this news could signal progress in IDEAYA's drug development efforts, potentially impacting the company's valuation if the results are positive. However, it's important to note that Phase 1 data, while promising, is still early-stage and further clinical trials will be necessary to confirm efficacy and safety.
Details for the oral presentation are as follows:
Presenter: Dr. Benjamin Herzberg, MD, Assistant Professor,
Title: Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor (MAT2Ai) in MTAP deleted(del) non-small cell lung cancer (NSCLC) and urothelial cancer (UC)
Abstract #: 501 LBA
Session: Plenary Session 7, Late Breaking Abstracts and Proffered Papers: Novel discoveries in drug development
Date and Time: Friday, October 25, 2024 at 3:00pm CEST
Poster presentation details are below:
Author: Garbett, D. et al.
Title: The mechanistic basis of both deep and durable antitumor activity by combinatorial inhibition of MAT2A and PRMT5 in MTAP-deleted tumors
Poster Number: PB204
Session Title: Combination Therapies
Date and Time: Thursday, October 24, 2024, 9:00am - 5:30pm CEST, Exhibition Hall
Author: Munoz, D. et al.
Title: IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets solid tumors with replication stress and DNA repair vulnerabilities
Poster Number: PB337
Session Title: DNA Repair Modulation (e.g. PARP, CHK, ATR, ATM)
Date and Time: Friday, October 25, 2024, 9:00am - 3:00pm CEST, Exhibition Hall
The oral presentation and posters will be available online at https://ir.ideayabio.com/events following the presentations.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the timing and content of future presentations. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K dated February 20, 2024 and any current and periodic reports filed with the
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-late-breaker-oral-presentation-of-ide397-phase-1-expansion-results-in-mtap-deletion-lung-and-urothelial-cancer-at-the-36th-edition-of-the-eortc-nci-aacr-symposium-302267595.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
What is IDE397 and what types of cancer does it target?
When and where will IDEAYA Biosciences (IDYA) present the Phase 1 expansion results for IDE397?
What other research will IDEAYA Biosciences (IDYA) present at the EORTC-NCI-AACR Symposium in October 2024?
Who will present the IDE397 Phase 1 expansion results for IDEAYA Biosciences (IDYA)?
